Melanie Greenland
MSc BSc
Medical Statistician
Melanie is a Medical Statistician at the Oxford Vaccine Group with experience of clinical trials in vaccinology, women's reproductive health, obstetrics and neonatal research. She also has experience in epidemiology in cardiovascular research using linked electronic health data and Biobank data. She holds a BSc in Mathematics and MSc in Biometry. She joined the team in 2020 and is currently involved in COVID, typhoid fever and pregnancy vaccine trials.
Recent publications
-
Cost-Utility Analysis of Planned Early Delivery or Expectant Management for Late Preterm Pre-eclampsia (PHOENIX).
Journal article
Hunter R. et al, (2022), Pharmacoecon Open
-
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Journal article
Shaw RH. et al, (2022), Lancet Respir Med
-
Towards better reporting of the Proportion of Days Covered method in cardiovascular medication adherence: A scoping review and new tool TEN-SPIDERS.
Journal article
Dalli LL. et al, (2022), Br J Clin Pharmacol
-
Two-year follow-up of infant and maternal outcomes after planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial.
Journal article
Beardmore-Gray A. et al, (2022), BJOG
-
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2021), Lancet